Filing Details
- Accession Number:
- 0001209191-20-045101
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-08-05 16:20:47
- Reporting Period:
- 2020-08-03
- Accepted Time:
- 2020-08-05 16:20:47
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1661567 | Michael Parini | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Chief Adm, Leg & Bd Off | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-08-03 | 2,330 | $86.52 | 29,168 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-08-03 | 500 | $276.98 | 28,668 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-08-03 | 1,100 | $278.13 | 27,568 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-08-03 | 730 | $279.41 | 26,838 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-08-03 | 2,330 | $0.00 | 2,330 | $86.52 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
4,660 | 2027-02-02 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $276.98 (range $276.60 to $277.39).
- Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $278.13 (range $277.73 to $278.58).
- Open market sales reported on this line occurred at a weighted average price of $279.41 (range $279.03 to $279.70).
- The option vests in 16 quarterly installments from 02/03/2017.